Scholarlink

<p>In 1997, the monoclonal antibody A4.6.1 was humanized to create Bevacizumab (Avastin, Genentech), an antibody suitable for clinical trials. In February 2004, Bevacizumab was approved in a randomized double-blind phase III study in which was administered in combination with bolus IFL (irinotecan, 5FU, leucovorin) chemotherapy as first-line therapy for previous untreated metastatic colorectal cancer. In 2020, the EMA approved the first biosimilar of Bevacizumab for the treatment of multiple types of cancer. The administration of Bevacizumab became popular among ophthalmologists for different ocular diseases. However, in most cases of cancers, including breast, melanoma, pancreatic and prostate cancer, Bevacizumab failed to increase survival. Despite impressive performances in animal models, however, inhibitors are not performing nearly as well in humans. The limitations of applying Bevacizumab are attributed to drug resistance, metastasis promotion and reduced delivery of chemotherapeutic agents, resulting from the dramatic decrease in tumor vasculature.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The discovery of Bevacizumab. An historical reappraisal

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月17日

查看全文
  • Domenico Ribatti

摘要

In 1997, the monoclonal antibody A4.6.1 was humanized to create Bevacizumab (Avastin, Genentech), an antibody suitable for clinical trials. In February 2004, Bevacizumab was approved in a randomized double-blind phase III study in which was administered in combination with bolus IFL (irinotecan, 5FU, leucovorin) chemotherapy as first-line therapy for previous untreated metastatic colorectal cancer. In 2020, the EMA approved the first biosimilar of Bevacizumab for the treatment of multiple types of cancer. The administration of Bevacizumab became popular among ophthalmologists for different ocular diseases. However, in most cases of cancers, including breast, melanoma, pancreatic and prostate cancer, Bevacizumab failed to increase survival. Despite impressive performances in animal models, however, inhibitors are not performing nearly as well in humans. The limitations of applying Bevacizumab are attributed to drug resistance, metastasis promotion and reduced delivery of chemotherapeutic agents, resulting from the dramatic decrease in tumor vasculature.